FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008171371> ?p ?o ?g. }

• W2008171371 abstract "Introduction: Recent clinical trials suggest that use of erythropoietin to treat chemotherapy-induced anemia results in enhanced tumor progression and impaired survival in certain cancer patients. Rationalizing these observations with Epo9s pleiotropic functionality and the lack of compelling evidence for Epo receptor (EpoR) involvement, we hypothesized the existence of a novel Epo receptor. Capturing this premise in terms of a holistic in silico strategy, we analyzed the secreted human proteome for receptors possessing structural, regulatory and functional features consistent with Epo binding and subsequent tumorigenic signaling. Our results provided EphB4 as the most likely candidate molecule. Methods: To determine the possible association between EphB4 and Epo-mediated tumor growth, we examined several ovarian (A2780, HeyA8-MDR, SKOV3ip1) and breast (MDA-231) cancer cell lines. In addition, we selected A2780 ovarian cancer cells to develop stable clones in which either EpoR or EphB4 was silenced using shRNA (A2780 shEpoR, A2780 shEphB4). Competitive and kinetic binding studies were performed using 125 I- Epo. Proliferation, migration, and invasion assays were performed as described previously. To assess the role of EpoR and EphB4 in Epo-induced tumor growth, we silenced EpoR and/or EphB4 with specific siRNAs loaded into DOPC nanoliposomes. Statistical significance was established at p Results: Binding studies with 125 I- Epo revealed Epo binding to EphB4 in a low-affinity fashion. Exposure of shEpoR cells to soluble EpoR showed non-competitive inhibition; however, exposure to soluble EphB4 competitively inhibited 125 I- Epo binding. These results demonstrate the specificity of Epo binding to the EphB4 receptor. At pharmacologically relevant doses, Epo treatment of shEpoR cells led to activation of the Stat-3 pathway. In addition, in vitro functional assays revealed significant effects of Epo on proliferation (p=0.003), migration (p=0.006), and invasion (p=0.02) of shEpoR cells, but not shEphB4 cells. In orthotopic ovarian (Hey-A8 MDR, SKOV3ip1, A2780) and breast (MDA-231) cancer models, treatment with Epo resulted in increased tumor growth compared to untreated animals (1.1 vs. 1.6 g, p=0.05; 0.7 vs. 1.75 g, p=0.03; 0.6 vs. 1.5 g, p=0.02; .012 vs 0.4 g, p=0.006), respectively. In vivo, (A2780 and MDA-231 models), EpoR siRNA did not affect Epo-stimulated tumor growth. In contrast, EphB4 siRNA-DOPC completely blocked Epo-stimulated tumor growth. Conclusions: Collectively, these results point to EphB4 as an alternative Epo receptor that mediates Epo-induced tumor growth by activating Stat-3. These findings offer exciting theranostic avenues for management of anemic cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1618. doi:10.1158/1538-7445.AM2011-1618" @default.
• W2008171371 created "2016-06-24" @default.
• W2008171371 creator A5000713007 @default.
• W2008171371 creator A5006094386 @default.
• W2008171371 creator A5006250220 @default.
• W2008171371 creator A5009043320 @default.
• W2008171371 creator A5009442045 @default.
• W2008171371 creator A5015358604 @default.
• W2008171371 creator A5017773172 @default.
• W2008171371 creator A5018166981 @default.
• W2008171371 creator A5022224126 @default.
• W2008171371 creator A5023542865 @default.
• W2008171371 creator A5026895259 @default.
• W2008171371 creator A5037193058 @default.
• W2008171371 creator A5042760638 @default.
• W2008171371 creator A5043280625 @default.
• W2008171371 creator A5048675624 @default.
• W2008171371 creator A5053228187 @default.
• W2008171371 creator A5054033791 @default.
• W2008171371 creator A5056412473 @default.
• W2008171371 creator A5063135953 @default.
• W2008171371 creator A5071614801 @default.
• W2008171371 creator A5072676659 @default.
• W2008171371 creator A5083750176 @default.
• W2008171371 date "2011-04-15" @default.
• W2008171371 modified "2023-10-17" @default.
• W2008171371 title "Abstract 1618: Erythropoietin meets a new receptor" @default.
• W2008171371 doi "https://doi.org/10.1158/1538-7445.am2011-1618" @default.
• W2008171371 hasPublicationYear "2011" @default.
• W2008171371 type Work @default.
• W2008171371 sameAs 2008171371 @default.
• W2008171371 citedByCount "1" @default.
• W2008171371 countsByYear W20081713712015 @default.
• W2008171371 crossrefType "proceedings-article" @default.
• W2008171371 hasAuthorship W2008171371A5000713007 @default.
• W2008171371 hasAuthorship W2008171371A5006094386 @default.
• W2008171371 hasAuthorship W2008171371A5006250220 @default.
• W2008171371 hasAuthorship W2008171371A5009043320 @default.
• W2008171371 hasAuthorship W2008171371A5009442045 @default.
• W2008171371 hasAuthorship W2008171371A5015358604 @default.
• W2008171371 hasAuthorship W2008171371A5017773172 @default.
• W2008171371 hasAuthorship W2008171371A5018166981 @default.
• W2008171371 hasAuthorship W2008171371A5022224126 @default.
• W2008171371 hasAuthorship W2008171371A5023542865 @default.
• W2008171371 hasAuthorship W2008171371A5026895259 @default.
• W2008171371 hasAuthorship W2008171371A5037193058 @default.
• W2008171371 hasAuthorship W2008171371A5042760638 @default.
• W2008171371 hasAuthorship W2008171371A5043280625 @default.
• W2008171371 hasAuthorship W2008171371A5048675624 @default.
• W2008171371 hasAuthorship W2008171371A5053228187 @default.
• W2008171371 hasAuthorship W2008171371A5054033791 @default.
• W2008171371 hasAuthorship W2008171371A5056412473 @default.
• W2008171371 hasAuthorship W2008171371A5063135953 @default.
• W2008171371 hasAuthorship W2008171371A5071614801 @default.
• W2008171371 hasAuthorship W2008171371A5072676659 @default.
• W2008171371 hasAuthorship W2008171371A5083750176 @default.
• W2008171371 hasConcept C104317684 @default.
• W2008171371 hasConcept C121608353 @default.
• W2008171371 hasConcept C126322002 @default.
• W2008171371 hasConcept C134018914 @default.
• W2008171371 hasConcept C170493617 @default.
• W2008171371 hasConcept C2775905019 @default.
• W2008171371 hasConcept C2778534260 @default.
• W2008171371 hasConcept C2780427987 @default.
• W2008171371 hasConcept C31102739 @default.
• W2008171371 hasConcept C502942594 @default.
• W2008171371 hasConcept C55493867 @default.
• W2008171371 hasConcept C71924100 @default.
• W2008171371 hasConcept C86803240 @default.
• W2008171371 hasConceptScore W2008171371C104317684 @default.
• W2008171371 hasConceptScore W2008171371C121608353 @default.
• W2008171371 hasConceptScore W2008171371C126322002 @default.
• W2008171371 hasConceptScore W2008171371C134018914 @default.
• W2008171371 hasConceptScore W2008171371C170493617 @default.
• W2008171371 hasConceptScore W2008171371C2775905019 @default.
• W2008171371 hasConceptScore W2008171371C2778534260 @default.
• W2008171371 hasConceptScore W2008171371C2780427987 @default.
• W2008171371 hasConceptScore W2008171371C31102739 @default.
• W2008171371 hasConceptScore W2008171371C502942594 @default.
• W2008171371 hasConceptScore W2008171371C55493867 @default.
• W2008171371 hasConceptScore W2008171371C71924100 @default.
• W2008171371 hasConceptScore W2008171371C86803240 @default.
• W2008171371 hasLocation W20081713711 @default.
• W2008171371 hasOpenAccess W2008171371 @default.
• W2008171371 hasPrimaryLocation W20081713711 @default.
• W2008171371 hasRelatedWork W2041037669 @default.
• W2008171371 hasRelatedWork W2048675139 @default.
• W2008171371 hasRelatedWork W2059886311 @default.
• W2008171371 hasRelatedWork W2074657894 @default.
• W2008171371 hasRelatedWork W2122584651 @default.
• W2008171371 hasRelatedWork W2313411379 @default.
• W2008171371 hasRelatedWork W2318954565 @default.
• W2008171371 hasRelatedWork W2324954137 @default.
• W2008171371 hasRelatedWork W2329142505 @default.
• W2008171371 hasRelatedWork W2331704598 @default.
• W2008171371 hasRelatedWork W2333847152 @default.
• W2008171371 hasRelatedWork W2398652208 @default.
• W2008171371 hasRelatedWork W2461562722 @default.
• W2008171371 hasRelatedWork W2483639988 @default.
• W2008171371 hasRelatedWork W2565667789 @default.

• next